CA2671727C - A composition containing a bisphosphonic acid in combination with vitamin d - Google Patents

A composition containing a bisphosphonic acid in combination with vitamin d Download PDF

Info

Publication number
CA2671727C
CA2671727C CA2671727A CA2671727A CA2671727C CA 2671727 C CA2671727 C CA 2671727C CA 2671727 A CA2671727 A CA 2671727A CA 2671727 A CA2671727 A CA 2671727A CA 2671727 C CA2671727 C CA 2671727C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
vitamin
bisphosphonic acid
glidant
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2671727A
Other languages
English (en)
French (fr)
Other versions
CA2671727A1 (en
Inventor
Mostafa Akbarieh
Fazal M. Mohideen
Shetal Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Pharmaceuticals ULC
Original Assignee
Mylan Pharmaceuticals ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Pharmaceuticals ULC filed Critical Mylan Pharmaceuticals ULC
Priority to CA2671727A priority Critical patent/CA2671727C/en
Publication of CA2671727A1 publication Critical patent/CA2671727A1/en
Application granted granted Critical
Publication of CA2671727C publication Critical patent/CA2671727C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2671727A 2006-12-20 2007-12-19 A composition containing a bisphosphonic acid in combination with vitamin d Expired - Fee Related CA2671727C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2671727A CA2671727C (en) 2006-12-20 2007-12-19 A composition containing a bisphosphonic acid in combination with vitamin d

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CA2,571,538 2006-12-20
CA2571398 2006-12-20
CA2571538 2006-12-20
CA2,571,398 2006-12-20
CA2671727A CA2671727C (en) 2006-12-20 2007-12-19 A composition containing a bisphosphonic acid in combination with vitamin d
PCT/CA2007/002313 WO2008074144A1 (en) 2006-12-20 2007-12-19 A composition containing a bisphosphonic acid in combination with vitamin d

Publications (2)

Publication Number Publication Date
CA2671727A1 CA2671727A1 (en) 2008-06-26
CA2671727C true CA2671727C (en) 2016-02-16

Family

ID=39535941

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2671727A Expired - Fee Related CA2671727C (en) 2006-12-20 2007-12-19 A composition containing a bisphosphonic acid in combination with vitamin d

Country Status (6)

Country Link
US (1) US20100179110A1 (https=)
EP (2) EP2124963A4 (https=)
JP (1) JP2010513328A (https=)
AU (1) AU2007335155A1 (https=)
CA (1) CA2671727C (https=)
WO (1) WO2008074144A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
KR101230178B1 (ko) 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
PT106978A (pt) * 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d
GR1008440B (el) * 2014-01-14 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα που περιλαμβανει συνδυασμο διφωσφωνικων και χοληκαλσιφερολης και μεθοδος για την παρασκευη αυτου

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042531A (en) * 1959-12-09 1962-07-03 Leslie Salt Company Method of making a compressed tablet
US4330537A (en) 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3512536A1 (de) 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
GEP20053654B (en) * 2001-05-01 2005-11-10 Pfizer Prod Inc Method For Manufacturing Low Dose Pharmaceutical Composition Having Uniform Drug Distribution
IL159853A0 (en) * 2001-07-17 2004-06-20 Teva Pharma Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
PL371259A1 (pl) * 2001-12-21 2005-06-13 Pfizer Products Inc. Bezpośrednio sprasowywalne preparaty azytromycyny
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
WO2004058235A2 (en) * 2002-12-16 2004-07-15 Teva Pharmaceutical Industries Ltd. Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
AU2004315136B2 (en) * 2004-02-04 2010-06-17 Alembic Limited Extended release coated microtablets of venlafaxine hydrochloride
BRPI0418756A (pt) * 2004-05-19 2007-09-11 Merck & Co Inc composições e métodos para inibir a reabsorção óssea
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption

Also Published As

Publication number Publication date
EP2124963A4 (en) 2010-03-17
EP2561877A1 (en) 2013-02-27
AU2007335155A1 (en) 2008-06-26
JP2010513328A (ja) 2010-04-30
WO2008074144A1 (en) 2008-06-26
US20100179110A1 (en) 2010-07-15
EP2124963A1 (en) 2009-12-02
CA2671727A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
US20050026871A1 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
US20030158154A1 (en) Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
JP2011241221A (ja) ビタミンｄ誘導体の前用量投与によってアレンドロネート等のビスフォスフォネートの生体利用効率を高める方法
CA2671727C (en) A composition containing a bisphosphonic acid in combination with vitamin d
DE69837450T2 (de) Alendronate zur Behandlung von Osteoporose
EP1651191B1 (en) Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use
US20050142185A1 (en) Softgel formulations of bisphosphonates bone resorption inhibitors
DE20321698U1 (de) Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats
AU2014215992A1 (en) A composition containing a bisphosphonic acid in combination with vitamin D
HK1182623A (en) A composition containing a bisphosphonic acid in combination with vitamin d
US20100120723A1 (en) Pharmaceutical composition comprising a hot-melt granulated lubricant
JPH10509729A (ja) 骨粗鬆症治療サイクル用キット
DE102004034043A1 (de) Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
AU2014201170B2 (en) Pharmaceutical composition comprising a hot-melt granulated lubricant
WO2012093977A1 (en) Water soluble pharmaceutical formulations comprising ibandronate and an inorganic salt for use in treatment of bone diseases
WO2012093976A1 (en) A composition comprising ibandronate at least 50 % of a filling agent and a sweetener
WO2012093975A1 (en) Water soluble formulations comprising ibandronate sodium with a water content less than 11 % by weight
US20140356423A1 (en) Formulations of lycopene in combination with bisphosphonates bone resorption inhibitors
KR20130012044A (ko) 증가된 비스포스포네이트의 생체이용률을 가지는 경구투여 약제
EP2661262A1 (en) Improved bisphosphonate formulations
CN110604309A (zh) 一种辅助预防骨质疏松的营养补充剂
CN110833547A (zh) 吡唑并嘧啶衍生物在治疗类风湿关节炎的用途
MXPA97004105A (en) Set for use in a therapeutic treatment cycle of osteoporo

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121219

MKLA Lapsed

Effective date: 20201221